Clinical trials
Amyloid clinical trials
Below are recruiting amyloid clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05806697Recruiting
Study of brain scan clues in people worried about memory
This extension study looks for predictors—measurable clues—linked to memory changes in older adults who feel their memory is worsening. You may be asked to have an amyloid PET scan, which can help researchers understand what might be driving memory concerns.
Paris, Île-de-France RegionAges 70–95 - NCT06032026RecruitingEarly Phase 1
Brain imaging study of tracer distribution in Parkinson's and related conditions
This study uses a special imaging tracer to see how it moves through the body and brain. It may help researchers understand brain changes in Parkinson's disease and related conditions.
Philadelphia, PennsylvaniaAges 40–80 - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT06091319Recruiting
Florbetaben imaging for vascular amyloid after heart or brain event
This trial tests whether florbetaben, a special dye, can show amyloid buildup in blood vessels after a recent heart attack, chest pain episode, or stroke. It aims to help doctors better understand and prevent future events.
Ottawa, OntarioAges 18 years+ - NCT06121544Recruiting
Pre-Alzheimer's Study: Find Early Brain Changes
This study is looking for healthy volunteers to help detect the very earliest signs of Alzheimer's disease—before memory loss starts. You will have tests like memory checks, blood draws, brain scans, and a spinal tap to look for Alzheimer's-related changes.
MalmöAges 50–80 - NCT06122415Recruiting
Memory clinic study with fluid and cognitive tests
This study looks at people who are being checked for memory or thinking problems. It uses standard tests done at the memory clinic, like a spinal tap and blood draw, plus memory and thinking tests, to learn more about these symptoms. You can join if these tests are already planned as part of your regular care, even if you don't take part in the study.
MalmöAges Any age - NCT06251778Recruiting
National study of ATTR heart amyloid patients on tafamidis
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
PaviaAges 18–99 - NCT06303921RecruitingEarly Phase 1
Study of a new brain imaging agent for Parkinson's disease
This trial uses a special PET scan to see how a new imaging agent (called 11C-M503) travels through the body and brain. It may help researchers better understand brain conditions like Parkinson's disease.
New Haven, ConnecticutAges 40–85 - NCT06318260RecruitingPhase 1/Phase 2
Dobutamine for heart failure in wild-type ATTR amyloidosis
This trial tests whether dobutamine, a heart-strengthening medicine, can improve blood flow and symptoms in people with a specific type of amyloidosis that affects the heart and who are already on water pills.
AarhusAges 65 years+ - NCT06338696Recruiting
Thailand ATTR-CM patient registry
This registry collects information from people with ATTR-CM, a condition where abnormal protein builds up in the heart. By joining, you help researchers learn more about the disease and improve future care.
BangkokAges 18–100 - NCT06372821RecruitingPhase 1
Study of NIO752 for Alzheimer's disease
This study tests an experimental drug called NIO752 to see if it can reduce the production of tau protein, which is linked to Alzheimer's disease. Researchers will measure how the drug affects tau in your body using a special technique called SILK.
St Louis, MissouriAges 21–80 - NCT06439992Recruiting
New PET scan tracer to detect Alzheimer's in the brain
This study tests a new PET imaging tracer called Fluselenamyl to see how well it shows amyloid plaques (a protein linked to Alzheimer's) in the brain. It may help improve early diagnosis for people with Alzheimer's or support research in healthy volunteers.
St Louis, MissouriAges 18 years+ - NCT06455748Recruiting
Daratumumab combo for new AL amyloidosis
This trial tests a combination of three drugs — daratumumab, pomalidomide, and dexamethasone — for people newly diagnosed with AL amyloidosis. The goal is to see if this treatment helps reduce the abnormal proteins and improve organ function.
Wenzhou, ZhejiangAges 18–80 - NCT06481878Recruiting
Testing a stool test for Alzheimer’s markers
This study checks if Alzheimer’s-related proteins (amyloid and tau) can be found in stool samples. It may help develop a simple, non-invasive way to detect Alzheimer’s disease.
GrenobleAges 40 years+ - NCT06539169Recruiting
Following people with rare diseases over time
This study follows people with rare diseases over time to learn more about how these conditions progress and how they are treated. Joining may help researchers understand your disease better and find better ways to care for others.
Los Altos, CaliforniaAges Any age - NCT06547099Recruiting
Understanding new blood markers in memory loss and dementia
This study is looking for older adults (60+) to help researchers better understand how to detect and track memory changes and dementia. Participants will provide blood samples and other health information over time to identify new markers that might help with early diagnosis.
St Louis, MissouriAges 60 years+ - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT07689331Recruiting
Hungarian national amyloidosis study
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
BalatonfüredAges 18 years+ - NCT06618872Recruiting
Comparing tau and amyloid PET scans for memory problems
This study compares two types of brain PET scans (tau and amyloid) to see which one better helps diagnose memory problems. You may be eligible if you have mild cognitive impairment or mild dementia and your doctor has already ordered an amyloid PET scan.
Geneva, Canton of GenevaAges 50–85 - NCT07602582RecruitingPhase 3
Donanemab Extension Study for Alzheimer's Disease
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
Phoenix, ArizonaAges 55 years+ - NCT06733714Recruiting
Brain stimulation plus memory training for older adults
This study tests whether a gentle, non-invasive electrical current applied to the scalp (tACS) combined with computer-based brain exercises can improve memory and thinking in older adults who have concerns about their cognitive health.
Rio de Janeiro, Rio de JaneiroAges 50 years+ - NCT06757569Recruiting
New PET scan for detecting amyloid plaques in the brain
This study tests a newer, shorter PET scan to see if it can detect amyloid plaques (sticky protein clumps linked to memory loss) as well as the standard scan. It may help diagnose cognitive problems with less time in the scanner.
Toronto, OntarioAges 18 years+ - NCT06786676RecruitingPhase 1
Safety study of AS-S603 in healthy volunteers
This trial tests a new drug called AS-S603 in healthy volunteers to see if it is safe and how the body processes it. It is an early-phase study for people of Korean or Caucasian background.
SeoulAges 19–85 - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+
Hear when a new Amyloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloid?
- Yes. Clin2 currently lists 87 recruiting amyloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.